Prime Highlights
- Pfizer’s 2026 outlook signals a transition phase as the company shifts from pandemic-driven revenues toward growth powered by its expanding drug pipeline.
- Despite short-term headwinds, the company remains confident that strategic acquisitions and research investments will support sustainable growth in the coming years.
Key Facts
- Pfizer expects adjusted earnings of $2.80 to $3 per share in 2026, with revenue projected between $59.5 billion and $62.5 billion.
- The company is targeting more than $7 billion in cost savings by 2027, with the majority of those reductions expected to be achieved by next year.
Background
Pfizer on Tuesday projected a measured financial outlook for 2026, reflecting continued pressure from declining Covid-related sales and the impact of older medicines losing exclusivity, even as the company invests heavily in its future drug pipeline.
The U.S. drugmaker said it expects adjusted earnings next year to range between $2.80 and $3 per share, with revenue forecast at $59.5 billion to $62.5 billion. While the guidance points to limited near-term growth, Pfizer emphasized that its strategy is centered on building sustainable revenue streams over the longer term.
The outlook also reflects pressure from patent expirations. Pfizer said it anticipates another $1.5 billion decline in sales due to certain products losing market exclusivity, with major expirations expected in 2026 and 2028. Chief Financial Officer Dave Denton told investors that about $17 billion in revenue will be affected by patent and regulatory exclusivity losses over that period.
Analysts largely viewed the guidance as expected. JPMorgan said the outlook reflects ongoing headwinds from Covid products and increased research spending, partially offset by restructuring efforts. Pfizer noted that it has exceeded its cost-saving targets for 2025 and is aiming for more than $7 billion in cost reductions by 2027, with most of those savings expected by next year.
The company also acknowledged pricing pressures tied to recent policy changes. Sales of its blood thinner Eliquis are set to face lower Medicare prices following government negotiations, and Pfizer said margin compression has been factored into its 2026 projections.
Despite the near-term challenges, Pfizer’s leadership expressed confidence in its long-term direction. Chief Executive Officer Albert Bourla said regulatory uncertainty around vaccines would not alter the company’s investment plans, adding that he expects current disruptions to normalize over time.
Pfizer recently reached a pricing agreement with the Trump administration that includes offering its drugs to Medicaid patients at prices comparable to those in other developed countries. In return, the company received a three-year exemption from pharmaceutical-specific tariffs.
Taken together, Pfizer’s 2026 outlook underscores a period of transition, one marked by short-term financial pressure, but supported by cost discipline, strategic acquisitions and a pipeline designed to drive growth beyond the current cycle.
